Welcome to Nofinity

In this podcast episode, Andrew Huberman speaks with Dr. Kyle Gillett about optimizing male hormones. Dr. Gillett emphasizes that hormone optimization is a lifelong process, starting from puberty and extending across the lifespan. He compares it to a new car that needs a full diagnostic check.

• Diet and Exercise: A balanced diet with adequate protein, vitamin D, and fiber is essential. Dr. Gillett warns against extreme diets (e.g., pure vegan or carnivore) in young people, as they can lower free androgens. Exercise should be vigorous 3-4 times a week (max 1 hour) with moderate activity on other days.
• Sleep: Especially important during puberty and in the 20s/30s for hormone production (e.g., growth hormone).
• Stress Management: Chronic stress can negatively impact all other lifestyle factors. Dr. Gillett recommends finding a life purpose (self-actualization per Maslow) and setting realistic, changeable goals.

• Testosterone and SHBG (Sex Hormone-Binding Globulin): High SHBG binds testosterone and reduces free androgens. Free testosterone and SHBG should be measured.
• Vitamin D: A deficiency should be corrected, as it supports testosterone production.
• Homocysteine: An inflammatory marker that may indicate a need for betaine or other supplements.

• Creatine (3-5 g/day): Slightly increases total testosterone and the conversion to DHT. No negative impact on hair loss, as it only restores natural levels.
• Betaine (1-3 g/day): Aids amino acid synthesis and is useful if homocysteine levels are high.
• L-Carnitine (1-5 g/day, oral): Increases the density of androgen receptors in cells, allowing more testosterone to bind. Caution: High doses can produce TMAO (a potential carcinogen); garlic or berberine can reduce this.
• Vitamin D3: Can optimize testosterone levels if deficient.
• Boron (5-12 mg/day): Acutely lowers high SHBG, increasing free testosterone.
• Tongkat Ali (Longjack, 300-1,200 mg/day): Upregulates enzymes in the steroidogenesis cascade and increases free testosterone, especially during calorie-restricted or low-carb diets.
• Fadogia agrestis (300 mg/day or 600 mg every other day): Increases luteinizing hormone (LH), which stimulates testosterone release. Higher doses may be toxic.

• When is TRT appropriate? Only for confirmed low levels, e.g., below 300 ng/dL, and typically later in life. For men in their 20s/30s with normal levels, TRT is almost never recommended, as it can impair fertility.
• Dosage and Frequency: A typical starting dose is 100-120 mg per week (e.g., 60 mg twice weekly) to achieve a physiological range. Higher doses (e.g., 200 mg/week) often exceed the reference range.
• Side Effects: Acne, hair loss, mood changes, elevated red blood cells (ferritin), lipid changes (LDL, ApoB), fertility issues. Regular medical monitoring (skin, heart, blood) is essential.

• Clomiphene is sometimes used as a short-term measure to avoid suppressing hypothalamic-pituitary function. Long-term use is not recommended due to side effects (e.g., vision changes).
• Tadalafil (Cialis, 2.5-5 mg/day): Used for prostate health and blood flow. It can increase androgen receptor density and reduce nighttime urination (nocturia), improving sleep and subsequent hormone production.

• Topical Alternatives: Caffeine and ketoconazole have weak anti-androgen effects. Topical finasteride reduces systemic DHT by about 30%, while topical dutasteride does not. Spironolactone should only be used with a prescription.

• Alcohol increases aromatase (conversion of testosterone to estrogen) and is high in calories. Dr. Gillett recommends no more than 3-4 standard drinks every two weeks.

Conclusion: A holistic approach with diet, exercise, sleep, and stress management is foundational. Supplements can support, but TRT and other medications should only be used under medical supervision and with clear indications.

Summary follows...

Summary follows...

Each year, the Federal Ministry of Labor sets the calculation figures for social insurance. The draft for 2027 brings notable increases, especially for high earners in health and long-term care insurance.

• Average earnings rise from €51,944 (2026) to €53,452 (+2.9%).
  → If your salary stagnates, you earn fewer pension points. You need a 2.9% raise just to keep your points stable.
• Contribution assessment ceiling rises from €101,400 to €106,200 (+4.7%).
  → Maximum contribution: €9,877 (€446 more than in 2026). Income above the ceiling is contribution-free but does not earn additional pension points.

• Contribution assessment ceiling jumps from €69,750 to €76,500 (+9.7%).
  Reason: The GKV Contribution Rate Stabilization Act adds a one-time extra of €300 per month (€3,600 per year) on top.
• Compulsory insurance threshold for switching to private health insurance rises from €77,400 to €84,150.

• At €69,750 annual income → no change.
• At €80,000 → +5% more contributions.
• Above €106,200 → +7% more contributions.

These increases come on top of regular contribution rate adjustments (e.g., rising supplementary contributions, a likely higher pension contribution rate from 2028, and possibly a higher long-term care surcharge for the childless).

Bitcoin has pulled back into the low $80k range, a zone that could determine how the rest of the year plays out. Although the price has retreated from recent highs, many indicators (like ETF inflows) still look solid. BlackRock and other ETF buyers continue to invest hundreds of millions, but buying pressure isn't translating into sustained upside.

• Bond Market: The US 10-year Treasury yield jumped to over 5%, the highest level since 2007. Safe assets become more attractive, draining liquidity from risk assets like Bitcoin.
• Fed Policy: The Fed raised interest rates by 25 basis points in September (first hike since July 2023). 16 of 18 officials project at least one more hike. A stronger dollar and uncertain rate expectations encourage de-risking.
• Internal Crypto Selling: Long-term holders realized profits on 25,700 BTC on September 22 (largest single day in 2026), especially in the $84k–$85k cluster. Leverage longs were also flushed: $230 million liquidated in one hour on September 23.

• $87k – Resistance where Bitcoin just failed. Reclaiming it would require multiple daily closes above and heavy ETF buying.
• $80k – Psychological round number and average ETF cost basis (~$81.7k). Losing it would put many new buyers underwater.
• $75k – Next support, reinforced by the 50-day moving average.

If $80k holds, it becomes the floor for the next leg up. If it breaks, expect prolonged chop and boredom, but not a crash ending the bull trend – long-term holders have unrealized gains of only ~72% (vs. 350% in December 2024). The next move will likely depend on expectations around the Fed and bond yields.

Summary follows...

🧨 Overview

This Octa episode focuses on the contrast between soft sentiment data and hard on-chain/market data. The key takeaway: Despite loud voices and manipulative players, hard data is the only reliable basis for investing decisions.

• CEX market makers continue to manipulate assets – investors are warned not to get destroyed by their actions.
• Consumer confidence is dismissed as “soft data” that doesn't necessarily signal a recession or bad AI earnings.
• Last week was mixed; Bitcoin dipped 4 % but remains 6 % up in September. The Fear & Greed Index stands at 73 (Greed).

• Bitcoin outperforms the S&P 500 in every bull run – hinting at rotating 401k funds into IBIT.
• Mike Novogratz predicts $100K by year-end; the $82K support may hold.
• The altcoin season index jumped from 47 to 57 – signaling a possible rotation into alts.

• DEXs are cheaper and faster than CEXs – clearly visible in fee and volume data.
• Solana leads tokenized equities (32 % volume) and app revenue ($5.42B – more than triple Ethereum's).
• AI agents will soon move funds out of banks – an “agentic bank run” that will eliminate all excess profits from banks.

• SpaceX proved massive cost efficiency: $200M payload for $5–10M launch cost. Orbital data centers (Starlink V3) are the next frontier.
• Elon Musk is training Grok on physical data (Tesla & SpaceX) – a huge competitive moat.
• A Tesla-SpaceX merger seems imminent; synergies could create the first $100 trillion company.
• Tesla sales remain strong: 3,000 per million people in Norway, ~1,000 per million in the US.

• Private construction is almost exclusively data centers – plenty of capacity in some markets.
• Open source will dominate most AI workloads, despite the “AI safety charade.”
• An October rate hike is now 70 % priced in, with diesel and oil prices rising.
• Closing anecdote: A Belgian student handed found crypto to the authorities – a refreshingly honest story.